Deferred Tax Assets and Other Non-Current Assets
Alnylam Pharmaceuticals Deferred Tax Assets and Other Non-Current Assets increased by 6.9% to $63.55M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.9%, from $73.82M to $63.55M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 5.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase generally suggests the accumulation of long-term economic benefits or tax recovery potential.
Detailed definition
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets that do not...
Peer comparison
Varies widely based on the specific composition of 'other' assets, making it a general indicator of long-term asset health.
deferred_tax_assets_other_noncurrentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.59M | $35.27M | $60.20M | $69.82M | $77.27M | $61.40M | $66.09M | $63.45M | $92.69M | $75.16M | $61.90M | $67.46M | $71.93M | $77.62M | $65.31M | $73.82M | $57.17M | $55.84M | $59.46M | $63.55M |
| QoQ Change | — | +2.0% | +70.7% | +16.0% | +10.7% | -20.5% | +7.6% | -4.0% | +46.1% | -18.9% | -17.6% | +9.0% | +6.6% | +7.9% | -15.9% | +13.0% | -22.6% | -2.3% | +6.5% | +6.9% |
| YoY Change | — | — | — | — | +123.4% | +74.1% | +9.8% | -9.1% | +20.0% | +22.4% | -6.3% | +6.3% | -22.4% | +3.3% | +5.5% | +9.4% | -20.5% | -28.1% | -9.0% | -13.9% |
Deferred Tax Assets and Other Non-Current Assets at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's deferred tax assets and other non-current assets?
- Alnylam Pharmaceuticals (ALNY) reported deferred tax assets and other non-current assets of $63.55M in Q1 2026.
- How has Alnylam Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Alnylam Pharmaceuticals's deferred tax assets and other non-current assets decreased by 13.9% year-over-year, from $73.82M to $63.55M.
- What is the long-term trend for Alnylam Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 5.7% compound annual growth rate (CAGR), from $45.05M to $59.46M.
- What does deferred tax assets and other non-current assets mean?
- The combined value of long-term tax assets and other miscellaneous long-term assets.